EGFR and hepatocellular carcinoma: Moreover, they developed hollow mesoporous silica NPs (HMSNs) to carry Sorafenib and CRISPR/Cas9 system targeting EGFR for combined therapy of HCC, and proved it was also a promising approach to enhance HCC treatment efficiency [88].